View in EDS HTML Full Text PDF Full Text

SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial.

Saved in:
Bibliographic Details
Title: SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial.
Authors: Mena Lora AJ; Division of Infectious Diseases, University of Illinois at Chicago, 808 S Wood St, RM 888, Chicago, IL 60612, USA., Enders K; University of North Carolina, Chapel Hill, NC, USA., Wu H; University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA., Parra-Rodriguez L; Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Palma C; University of Rochester, Rochester, NY, USA., Saliba K; National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Laverdurre S; Leidos Biomedical Research, Bethesda, MD, USA., Smith PB; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Anstrom KJ; University of North Carolina, Chapel Hill, NC, USA., Bozzette SA; National Center for Advancing Translational Sciences, Bethesda, MD, USA., Powderly WG; Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Source: Therapeutic advances in infectious disease [Ther Adv Infect Dis] 2025 Apr 22; Vol. 12, pp. 20499361251333617. Date of Electronic Publication: 2025 Apr 22 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 101606715 Publication Model: eCollection Cited Medium: Print ISSN: 2049-9361 (Print) Linking ISSN: 20499361 NLM ISO Abbreviation: Ther Adv Infect Dis Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40297751
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mena+Lora+AJ%22">Mena Lora AJ</searchLink>; Division of Infectious Diseases, University of Illinois at Chicago, 808 S Wood St, RM 888, Chicago, IL 60612, USA.<br /><searchLink fieldCode="AU" term="%22Enders+K%22">Enders K</searchLink>; University of North Carolina, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Wu+H%22">Wu H</searchLink>; University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.<br /><searchLink fieldCode="AU" term="%22Parra-Rodriguez+L%22">Parra-Rodriguez L</searchLink>; Washington University School of Medicine in St. Louis, St. Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Palma+C%22">Palma C</searchLink>; University of Rochester, Rochester, NY, USA.<br /><searchLink fieldCode="AU" term="%22Saliba+K%22">Saliba K</searchLink>; National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Laverdurre+S%22">Laverdurre S</searchLink>; Leidos Biomedical Research, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Smith+PB%22">Smith PB</searchLink>; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Anstrom+KJ%22">Anstrom KJ</searchLink>; University of North Carolina, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Bozzette+SA%22">Bozzette SA</searchLink>; National Center for Advancing Translational Sciences, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Powderly+WG%22">Powderly WG</searchLink>; Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101606715%22">Therapeutic advances in infectious disease</searchLink> [Ther Adv Infect Dis] 2025 Apr 22; Vol. 12, pp. 20499361251333617. <i>Date of Electronic Publication: </i>2025 Apr 22 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101606715 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2049-9361 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220499361%22">20499361 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Infect Dis <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40297751
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/20499361251333617
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 20499361251333617
    Titles:
      – TitleFull: SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mena Lora AJ
      – PersonEntity:
          Name:
            NameFull: Enders K
      – PersonEntity:
          Name:
            NameFull: Wu H
      – PersonEntity:
          Name:
            NameFull: Parra-Rodriguez L
      – PersonEntity:
          Name:
            NameFull: Palma C
      – PersonEntity:
          Name:
            NameFull: Saliba K
      – PersonEntity:
          Name:
            NameFull: Laverdurre S
      – PersonEntity:
          Name:
            NameFull: Smith PB
      – PersonEntity:
          Name:
            NameFull: Anstrom KJ
      – PersonEntity:
          Name:
            NameFull: Bozzette SA
      – PersonEntity:
          Name:
            NameFull: Powderly WG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 04
              Text: 2025 Apr 22
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2049-9361
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Therapeutic advances in infectious disease
              Type: main
ResultId 1